Quick Take
Poseida Therapeutics (PSTX) has filed to raise $115 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is advancing a broad pipeline of genetic and CAR-T-based therapies for blood, solid, and other cancers.
PSTX has achieved promising early-stage trial results for its co-lead candidates.
I'll provide an update when we learn more about the IPO from management.
Company & Technology
San Diego, California-based Poseida was founded to develop CAR-T and Cas-CLOVER genetic therapy approaches to treating cancers and other cancers.
Management is headed